Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Liposarcoma 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1

Interventions

Doxorubicin 8Ifosfamide 6Radiotherapy 4Filgrastim 2pembrolizumab 1pegfilgrastim 1olaratumab 1indolepropanol phosphate 1brigimadlin 1X-Rays 1Watchful Waiting 1Specimen Handling 1Radiotherapy, Conformal 1Observation 1Gemcitabine 1Etoposide 1Docetaxel 1Diathermy 1Combined Modality Therapy 1Chemotherapy, Adjuvant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Histiocytoma, Malignant Fibrous × brigimadlin × Clear all
NCT06370871 2024-07-17

Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

Boehringer Ingelheim

Phase 3 Withdrawn
Sarcoma

Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡